10x Genomics, Inc.
TXG
Classificação em ações
#2209
Headquartered in Pleasanton, California, 10x Genomics, Inc. (founded in 2012... Headquartered in Pleasanton, California, 10x Genomics, Inc. (founded in 2012 and known as 10X Technologies, Inc. until November 2014) is a prominent life science technology company. The firm specializes in creating and distributing sophisticated instrumentation, essential consumables, and software designed for in-depth analysis of biological systems. Its market presence extends globally, covering North America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company's offerings feature Chromium and Chromium Connect instruments, supported by indispensable items such as microfluidic chips, slides, and reagents. A significant portion of their portfolio focuses on single-cell solutions, leveraging their Chromium platforms. These allow for precise measurement of gene activity at the individual cell level (single cell gene expression), detailed assessment of immune cell function and their targets (single cell immune profiling), exploration of DNA's physical organization and epigenetic modifications (single cell Assay for Transposase Accessible Chromatin - ATAC), and the concurrent quantification of both genetic activity and epigenetic programming across tens of thousands of cells in a single experiment (single cell multiome ATAC + gene expression). Additionally, 10x Genomics offers the Visium spatial gene expression solution, which maps gene activity patterns within specific tissue sections and can also facilitate co-detection of gene expression and proteins when paired with immunofluorescence. Their varied customer base includes academic, governmental, biopharmaceutical, and biotechnology organizations, among others.
Preço da ação
$70.28
Última sincronização: 2026-10-19
Valor de mercado
$9.16B
Variação (1 dia)
0.60%
Variação (1 ano)
434.84%
País
US
Negociar 10x Genomics, Inc. (TXG)
Categoria
Healthcare
Lucros da 10x Genomics, Inc. (TXG)
Lucros em Jun 2026 TTM: $-74.89M
De acordo com os últimos relatórios financeiros da 10x Genomics, Inc., os ganhos atuais da empresa são de $-74.89M. Em 2024, a empresa teve ganhos de $-177.70M, um aumento em relação a aos ganhos de 2023, que foram de $-248.76M. Os ganhos apresentados nesta página são os ganhos antes de juros e impostos, conhecidos como EBIT.
Histórico de lucros da 10x Genomics, Inc. de 2017 a 2026
Lucros no final de cada ano
| Ano | Lucros | Alterar |
|---|---|---|
| 2026 (TTM) | $-74.89M | 87.66% |
| 2025 | $-39.91M | -77.54% |
| 2024 | $-177.70M | -28.57% |
| 2023 | $-248.76M | 53.58% |
| 2022 | $-161.97M | 201.54% |
| 2021 | $-53.72M | -89.95% |
| 2020 | $-534.48M | 1,622.28% |
| 2019 | $-31.03M | -72.39% |
| 2018 | $-112.40M | 499.74% |
| 2017 | $-18.74M | 0.00% |
Lucros de empresas semelhantes ou concorrentes
| Empresa | Lucros | Diferença de Lucros | País |
|---|---|---|---|
| $2.04B | -2,828.00% |
US
|
|
| $266.26M | -455.53% |
AU
|
|
| $295.53M | -494.62% |
US
|
|
| $-259.89M | 247.03% |
US
|
|
| - | - |
US
|
